Search for Clinical Trial Results

Sponsored By

Mucopolysaccharidosis II - 50 Studies Found

Status Study
Recruiting Study Name: Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
Condition: Mucopolysaccharidosis II
Date: 2014-10-02
Interventions: Drug: AGT-182 Recombinant HIRMAb-IDS
Completed Study Name: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
Condition: Mucopolysaccharidosis II
Date: 2003-09-29
Interventions:
  • Biological: Iduronate-2-sulfatase enzyme replacement therapy

Completed Study Name: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
Condition: Mucopolysaccharidosis II
Date: 2011-02-22
Interventions:
  • Drug: GC1111_0.5mg/kg
  • Drug: GC1111_1.0mg/k
Not yet recruiting Study Name: Study of Idursulfase-beta (GC1111) in Hunter Syndrome
Condition: Mucopolysaccharidosis II
Date: 2016-01-17
Interventions:
  • Biological: idursulfase beta I
Recruiting Study Name: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
Condition: Mucopolysaccharidosis II
Date: 2017-01-13
Interventions: Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
Completed Study Name: Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)
Condition: Mucopolysaccharidosis II
Date: 1999-10-18
Interventions: Genetic: lymphocyte gene therapy
Recruiting Study Name: A Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Condition: Mucopolysaccharidosis II
Date: 2017-04-10
Interventions: Drug: JR-141 IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
Recruiting Study Name: The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
Condition: Hunter Syndrome
Date: 2014-01-19
Completed Study Name: A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723
Condition: Mucopolysaccharidosis II
Date: 2012-05-17
Interventions:
  • Drug: Idursulfase recombinant

Completed Study Name: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Condition:
  • Hunter Syndrome
  • Mucopolysaccharidosis II<
    Date: 2008-02-28
    Interventions: Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly
Next >>>